News
Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.
Clinical Trials Arena on MSN5d
Oculis completes enrolment in trials for diabetic macular oedema eye dropsOculis Holding has concluded subject enrolment for the Phase III DIAMOND-1 and DIAMOND-2 clinical trials of OCS-01 eye drops ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback